- Neurocrine Biosciences (NBIX, Financial) confirmed the long-term efficacy and safety of INGREZZA® in treating tardive dyskinesia (TD) in older adults.
- 95% of participants aged 65 and older on an 80mg dose achieved significant improvement in symptoms by week 48.
- Safety profile of INGREZZA was consistent, with the most common side effects being urinary tract infection and somnolence.
Neurocrine Biosciences, Inc. (NBIX) has published a pivotal analysis in The Journal of Clinical Psychiatry, demonstrating the long-term efficacy and safety of INGREZZA® (valbenazine) capsules in adults aged 65 years and older suffering from tardive dyskinesia (TD). This represents the first peer-reviewed analysis of a vesicular monoamine transporter 2 (VMAT2) inhibitor targeting this demographic, highlighting its suitability for older patients at higher risk for TD.
The study pooled data from 304 participants in the KINECT 3 extension and KINECT 4 studies, including 55 individuals aged 65 and older. Within eight weeks of treatment with INGREZZA, older adults experienced clinically significant improvements in TD symptoms, sustained through 48 weeks. Specifically, 95% of participants on the 80mg dose achieved at least a 30% improvement on the Abnormal Involuntary Movement Scale (AIMS), with similar success rates reflected in the Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) and Patient Global Impression of Change (PGIC) scores.
The safety profile of INGREZZA remained consistent, with no new treatment-emergent adverse events of clinical concern compared to younger participants. Common side effects were urinary tract infections and somnolence, each occurring in six of the older participants. These findings bolster INGREZZA's clinical profile, potentially influencing prescribing practices in treating TD among geriatric populations.
